Eric Winer, MD (@DrEricWiner) header
Eric Winer, MD (@DrEricWiner) profile picture

Eric Winer, MD

@DrEricWiner

Director of @YaleCancer and President & Physician-in-Chief @SmilowCancer. Breast Cancer Medical Oncologist. Tweets are my own. #bcsm #mBCSM

 New Haven, CT
yalecancercenter.org
Joined October 2014
  • Tweets15
  • Following71
  • Followers5.2K
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
I am excited to be hosting Yale Cancer Answers and look forward to talking with our guests each week. This Sunday, I welcome Dr. Tamar Taddei to discuss challenges and advances in liver cancer.
Yale Cancer Center (@YaleCancer) profile pictureYale Cancer Center
@YaleCancer18 Jul 2024
We’re excited to announce @DrEricWiner as host of #YaleCancerAnswers, our weekly, award-winning radio show broadcast on @wnpr Sunday nights at 7:30pm. Stream anytime on @ApplePodcasts and @YouTube. yalecancercenter.org/news-ar… @SmilowCancer @YaleMed @YNHH
Image from Yale Cancer Center (@YaleCancer)
2
12
2,738
.@DrEricWiner shares perspective with @nytimes on @JAMAOnc study, “it suggests that there is absolutely no difference in survival if you have a lumpectomy, a mastectomy or a double mastectomy.” @SmilowCancer @YaleBreast @YaleMed @YNHH nytimes.com/2024/07/25/healt…
Breast Cancer Survival Not Boosted by Double Mastectomy, Study Says (Published 2024)

Breast Cancer Survival Not Boosted by Double Mastectomy, Study Says (Published 2024)

A large study showed that for most patients, having both breasts removed after cancer was detected in one made no difference.

nytimes.com
1
3
5
1,083
Research led by @DrRoyHerbstYale suggests that #NC318, both alone and in combination with pembrolizumab, improved response rates and clinical outcomes for some patients with #NSCLC. @SmilowCancer @YaleMed @YNHH @OncoAlert yalecancercenter.org/news-ar…
1
8
19
3,704
Eric Winer, MD retweeted
ASCO (@ASCO) profile picture
ASCO
@ASCO4 Aug 2023
“Opinion: The cancer drug shortage is a disgrace” -- read a just-published @CNN op-ed from our Board Chair & Past President @DrEricWiner on the current oncology #drugshortages: fal.cn/3AtEQ
9
2
27
7,420
Yale Cancer Center is filled with pride that Pat LoRusso is a nominee for @AACR president, with ballot opening today. We are all 100% behind her, and I know she will be an extraordinary leader for AACR. @YaleCancer @SmilowCancer
9
31
5
180
28,205
Fantastic to be back in Chicago @ASCO annual meeting. It feels like old times apart from all the masks -- making the name tags more important than ever before. Program clearly demonstrates that we have continued to make advances these past 2+ years. #ASCO22
2
20
359
I am profoundly sad to learn of the passing of Angelo Di Leo. He was so thoughtful, gentle, and creative. Saw Angelo 6/2019 and struck by his bravery and straightforward approach to his illness. He will be missed by entire cancer community. Am thinking of his wife + daughter.
8
10
2
136
Congrats to Dr. Lori Pierce on a brave, bold, and truly spectacular opening session. Presidential address truly moving. We are all wiser as a result. #asco21 @ASCOPres @ASCO
32
3
196
Thank you all for the congratulations and well wishes. I am thrilled and honored to be the @ASCO president-elect-elect. This is a tough winter, but we all just have to get through it and the future is bright. Thanks again!
46
25
15
610
Looks like neratinib/capecitabine is a reasonable option for 3rd line therapy and beyond for patients with metastatic HER2+ breast cancer. It would be interesting to know how neratinib/capecitabine would compare with trastuzumab/capecitabine. #ASCO19
3
6
1
37
Final Kristine results are enormously encouraging. Almost certainly, a combination of molecular markers and clinical response can identify a relatively large group of patients who will ultimately be able to receive T-DM1 +P alone and avoid standard cytoxic chemotherapy. Bravo.
1
14
4
65
Load more